Speedy EU approval for AZ's key new anticancer Lynparza
This article was originally published in Scrip
Executive Summary
AstraZeneca's first-in-class anticancer olaparaib has received its first worldwide approval in the EU as Lynparza for use in ovarian cancer, less than two months after it was given the go-ahead by the CHMP. The company told Scrip is was aiming to get Lynparza to market across the EU as quickly as possible and that the UK and some of the Nordic markets were likely to be among the first to launch it in 2015.